BDRX: SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for BDRX
Across the 8 sessions after earlier BDRX headlines, the stock closed higher 4 times and lower 4 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BDRX | SPY |
|---|---|---|---|
| Mar 9, 2026 | Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients | +4.9% | +0.9% |
| Feb 19, 2026 | Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer | +3.2% | -0.3% |
| Feb 4, 2026 | Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST | -11.0% | -0.5% |
| Jan 5, 2026 | Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary | +2.0% | +0.7% |
| Dec 18, 2025 | Biodexa Announces Pricing of $10 Million Public Offering | -24.0% | +0.8% |
| Dec 1, 2025 | Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP | +2.2% | -0.5% |
Quantisnow market dataNASDAQ
BDRX
Biodexa Pharmaceuticals plc American Depositary Shs
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for BDRX
Full BDRX profile on Quantisnow Follow BDRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time